TORONTO and DALLAS, May 23, 2023
/CNW/ - (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) –
Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") –
a commercial-stage medical technology company – announced that Dr.
Anthony Holler has resigned as a
director of the Company, effective immediately, for personal
reasons.
Jeremy Sobotta, Perimeter's Chief
Executive Officer stated, "We are grateful for Dr. Holler's many
contributions to Perimeter over the years during his tenure on the
Board – including his service as Chair from 2019 to 2022. On behalf
of the Perimeter team and Board, I thank Dr. Holler for his
commitment to Perimeter and wish him all the best in his future
endeavors."
About Perimeter Medical Imaging
AI, Inc.
Based in Toronto, Canada and
Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is
a medical technology company driven to transform cancer surgery
with ultra-high-resolution, real-time, advanced imaging tools to
address areas of high unmet medical need. Available across the
U.S., our FDA-cleared Perimeter S-Series OCT system provides
real-time, cross-sectional visualization of excised tissues at the
cellular level. The breakthrough-device-designated investigational
Perimeter B-Series OCT with ImgAssist AI represents our
next-generation artificial intelligence technology that is
currently being evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million
awarded by the Cancer Prevention and Research Institute of
Texas. The company's ticker symbol
"PINK" is a reference to the pink ribbons used during Breast Cancer
Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking
Statements
This news release contains statements that constitute
"forward-looking information" within the meaning of applicable
Canadian securities legislation. In this news release, words such
as "may," "would," "could," "will," "likely," "believe," "expect,"
"anticipate," "intend," "plan," "estimate," and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management's
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist; and the expected details regarding Perimeter's ongoing
clinical trials, are forward-looking information. Forward-looking
statements should not be read as guarantees of future performance
or results, and will not necessarily be accurate indications of
whether, or the times at or by which, any particular result will be
achieved. No assurance can be given that any events anticipated by
the forward-looking information will transpire or occur.
Forward-looking information is based on information available at
the time and/or management's good-faith belief with respect to
future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter's control. Such forward-looking
statements reflect Perimeter's current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter's
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter's
Management Discussion and Analysis for the year ended December 31, 2022, which is available on
Perimeter's SEDAR profile at www.sedar.com, and could cause actual
events or results to differ materially from those projected in any
forward-looking statements. Perimeter does not intend, nor does
Perimeter undertake any obligation, to update or revise any
forward-looking information contained in this news release to
reflect subsequent information, events, or circumstances or
otherwise, except if required by applicable laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-announces-resignation-of-director-301832071.html
SOURCE Perimeter Medical Imaging AI, Inc.